Clinical trials
Observational Leukemia trials in China
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
15 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2006 | 1 |
| 2011 | 1 |
| 2013 | 1 |
| 2017 | 2 |
| 2018 | 2 |
| 2020 | 3 |
| 2022 | 1 |
| 2023 | 1 |
| 2024 | 1 |
| 2026 | 2 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Unknown status | 6 |
| Recruiting | 4 |
| Completed | 3 |
| Active, not recruiting | 1 |
| Not yet recruiting | 1 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Peking University People's Hospital | 3 |
| National Cancer Institute (NCI) | 2 |
| The Children's Hospital of Zhejiang University School of Medicine | 2 |
| Children's Hospital of Chongqing Medical University | 1 |
| Institute of Hematology & Blood Diseases Hospital, China | 1 |
| Peking University First Hospital | 1 |
| Shenzhen Second People's Hospital | 1 |
| Sun Yat-sen University | 1 |
| Tianjin Medical University General Hospital | 1 |
| Yigeng Cao,MD,PhD | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Leukemia | 15 |
| Leukemia, Myeloid, Acute | 6 |
| Lymphoma | 5 |
| Myelodysplastic Syndromes | 3 |
| Anemia, Aplastic | 2 |
| Hemophilia A | 2 |
| Hemostatic Disorders | 2 |
| Multiple Myeloma | 2 |
| Anemia, Hemolytic, Autoimmune | 1 |
| Bronchiolitis Obliterans Syndrome | 1 |
Trials
Showing 1 to 15 of 15. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.